Frontiers in Laboratory Medicine最新文献

Objective

To explore the correlation of oxidative stress in patients with chronic hepatitis B and degree of severity of the disease with HBV genotype and drug-resistant mutation.

Methods

A total of 296 patients with diagnosed chronic hepatitis B were selected from Febuary 2014 to April 2016 in Mianyang Central Hospital, including 145 cases of chronic hepatitis B (CHB), 101 cases of hepatitis B cirrhosis (HBC), and 50 cases of hepatocellular carcinoma (HCC). Three HBV genotypes (B, C and D) and eight drug-resistant mutation genes (rt180L, rt204M, rt207V, rt236N, rt250M, rt181A, rt184T and rt202S) were detected by PCR-reverse dot blot method. In addition, total oxidative stress (TOS), and total antioxidant status (TAS) were measured, on the basis of which oxidative stress index (OSI) was calculated. Furthermore, the differences of TOS, TAS and OSI levels were compared between different liver diseases, different genotypes or drug-resistant mutation, and also the correlations were analyzed between HBV genotype, drug-resistant mutation, patient’s oxidative stress status and disease severity.

Results

Serum TOS and OSI levels, HBV-B/C ratios and drug-resistant mutation rates increased gradually with the severity of liver disease (CHB < HBC<HCC, P < 0.05). Serum TAS levels decreased with degree of severity of the disease, but there was no statistical difference between CHB group and HCC group. Except TAS levels in patients at PHC group, compared with patients without mutation in HBV, the patients with drug-resistant mutation had higher TOS and OSI levels, but lower serum TAS levels (P < 0.05). Drug-resistant mutation rate was positively correlated with TOS (r = 0.476, P < 0.001) and OSI (r = 0.441, P < 0.001) levels, but negatively correlated with TAS level (r = −0.249, P < 0.001), except TAS level in patients at PHC group. In addition, the number of mutation sites was positively correlated with disease severity (γ = 0.614, P < 0.001).

Conclusions

There are different degrees of oxidative damage in patients with HBV-induced liver disease, and the degree of the damage depends on HBV genotypes and drug-resistant mutations. Therefore, oxidative stress parameters might be useful indicators of progression of HBV-induced liver disease in patients.

Purpose

Long noncoding RNA (lncRNA) H19 has been reported to be up-regulated and down-regulated in numerous tumors, but the relevance of clinical pathological features is not established. So, meta-analysis was conducted to investigate the association between H19 expression and pathological features of cancers.

Method

The databases on PubMed, Web of Science, CNKI, and Wan Fang were searched for the related studies. 13 eligible studies were included with a total of 854 patients. Revman5.3 and Stata12.0 software were performed to analyze the data.

Results

The results suggested that the group of high H19 expression had a higher risk of poorly histological grade, clinical stage, deep tumor invasion (T2 stage or more), and was inclined to lymphatic metastasis, distant metastasis, and had a shorter survival time than the group of low H19 expression.

Conclusion

High expression of lncRNAH19 might act as a novel diagnostic biomarker and predict poor oncological outcomes of patients with cancers.

Objective

To explore the clinical efficacy of Nucleic acid testing (NAT) in combination with Enzyme linked immunosorbent assay (ELISA).

Methods

Between January 2015 and December 2016, 106,488 specimens from hospitalized patients were detected for HIV, HBV, and HCV by using NAT plus ELISA to compare the positive and negative coincidence rate in the same patient.

Results

99.85% (106,324) HIV results, 94.80% (100,951) HBV results and 99.45% (105,902) HCV results were identical by both tests. The results, showing NAT⁺/ELISA⁻, for HIV, HBV, and HCV were 21, 316 and 0 respectively, and the results, showing NAT⁺/ELISA⁻, for HIV, HBV, and HCV were 143, 4958 and 586 respectively.

Conclusions

The combination of NAT and ELISA could effectively improve the detection accuracy and screening efficiency for HIV, HBV and HCV, decrease the rate of missed detection, and reduce the risk of iatrogenic infection.

In the past several decades, multiple clinical trials have demonstrated the effects of dyslipidemia beyond low density lipoprotein cholesterol (LDL-C) on predicting risk for atherosclerosis and cardiovascular disease. In recent years there has been a proliferation of lipoprotein markers that, when used with LDL-C, help healthcare providers assess risk of patients on the basis of the cardiovascular risk spectrum. In this review, we will discuss some of the important reasons why traditional lipoprotein testing has failed in high risk populations and how unique lipoprotein testing by the Vertical Auto Profile (VAP) Lipid panel is to provide significant clarity to a difficult disease for its management and treatment. We will also discuss some of the new trials that address newer markers of risk that have robust outcomes even after adjusting for traditional cardiovascular disease risk factors.